Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 SARS-CoV-2 Infection Clear all
Not listed No phase listed Observational

The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey

NCT05312619
View directory record Official record
Conditions
COVID-19, Lyme Disease, COVID-19 Vaccine
Interventions
Cross sectional survey
Other
Lead sponsor
Dr. Daniel Cameron & Associates
Other
Eligibility
12 Years and older
Enrollment
2,000 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Mount Kisco, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

NCT04417257
View directory record Official record
Conditions
COVID-19 Disease
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Chandler, Arizona • Newport Beach, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

NCT05184192
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Anosmia, Hyposmia, Parosmia
Interventions
Gabapentin gelatin capsules 300mg, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 13, 2026, 10:58 PM EDT
No Longer Available No phase listed Expanded access

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04445207
View directory record Official record
Conditions
COVID, Sars-CoV2, Corona Virus Infection
Interventions
Convalescent Plasma
Biological
Lead sponsor
Jonathan Gerber
Other
Eligibility
12 Years and older
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 13, 2026, 10:58 PM EDT
Completed No phase listed Observational

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

NCT05256316
View directory record Official record
Conditions
COVID-19
Interventions
Previously admitted COVID-19 patients in intensive care units
Other
Lead sponsor
The University of Queensland
Other
Eligibility
18 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

NCT04379518
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Recombinant Interferon Alfa-2b, Rintatolimod
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated No phase listed Observational

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

NCT05044780
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HOPE Intervention for COVID-19

NCT04376515
View directory record Official record
Conditions
COVID-19 Vaccination
Interventions
HOPE intervention
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

NCT04784897
View directory record Official record
Conditions
COVID-19
Interventions
Brilacidin, Placebo, Standard of Care (SoC)
Drug
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Winfield, Illinois • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 13, 2026, 10:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Evaluation of Together for Wellness Website in COVID-19

NCT04961242
View directory record Official record
Conditions
Digital Mental Health Resources (Website) for Coping With Stress and Information
Interventions
Together for Wellness digital mental health website
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Not applicable Interventional

A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID

NCT06586398
View directory record Official record
Conditions
Long Covid-19, PASC Post Acute Sequelae of COVID 19, Brain Fog, Fatigue
Interventions
rTMS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT05543616
View directory record Official record
Conditions
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 11 Years
Enrollment
4,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

NCT04606784
View directory record Official record
Conditions
Covid19
Interventions
Ampion, Standard of Care
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 13, 2026, 10:58 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Elderberry for Immune Support

NCT05435144
View directory record Official record
Conditions
Upper Respiratory Tract Infection, COVID-19, Flu, Flu Like Illness, Cold
Interventions
Elderberry, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 13, 2026, 10:58 PM EDT
Withdrawn Not applicable Interventional

Core Warming of COVID-19 Patients

NCT04426344
View directory record Official record
Conditions
COVID 19
Interventions
ensoETM device
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 13, 2026, 10:58 PM EDT
Recruiting Not applicable Interventional

Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog

NCT06614309
View directory record Official record
Conditions
Long COVID
Interventions
Acute Placebo Visit, Acute Progressive Carbon Dioxide, Acute Intermittent Hypoxia, Training: Progressive Carbon Dioxide Ramping, Training: Intermittent Hypoxic Exposure, Training: Placebo Control
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed No phase listed Observational

Genetics of COVID-19 Susceptibility and Manifestations

NCT04371432
View directory record Official record
Conditions
COVID-19, Coronavirus 2019
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 110 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed No phase listed Observational Results available

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

NCT07072793
View directory record Official record
Conditions
COVID-19 (Coronavirus Disease 2019)
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
131,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19

NCT04372628
View directory record Official record
Conditions
COVID-19
Interventions
Lopinavir/Ritonavir 400 mg/100 mg, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 13, 2026, 10:58 PM EDT
Withdrawn Phase 2 Interventional

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

NCT04728698
View directory record Official record
Conditions
Covid19, ARDS
Interventions
COVI-MSC, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 13, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin in Respiratory Failure in Patients With COVID-19

NCT04350593
View directory record Official record
Conditions
COVID-19
Interventions
Dapagliflozin 10 milligram (mg), Placebo
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Fairhope, Alabama • Miami, Florida • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 13, 2026, 10:58 PM EDT
Withdrawn Phase 4 Interventional

Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)

NCT04565392
View directory record Official record
Conditions
Covid19
Interventions
Famotidine 20 milligram tablet
Drug
Lead sponsor
drpykessupplements.com
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Fairfield, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 13, 2026, 10:58 PM EDT